8. Huntington disease
197 clinical trials,   171 drugs   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03980938
(ClinicalTrials.gov)
July 8, 20197/6/2019Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington DiseaseA Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)Huntington DiseaseDrug: neflamapimod;Other: PlaceboEIP Pharma IncVoisin Consulting, Inc.Recruiting30 Years70 YearsAll16Phase 2United Kingdom
2EUCTR2018-004840-51-GB
(EUCTR)
26/06/201922/03/2019Study of Neflamapimod in Early-Stage Huntington Disease (HD)A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) Early-Stage Huntington Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EIP Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
16Phase 2United Kingdom